Clinical Trials · NCT05067621
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Yale University
- Enrollment
- 60
- Start date
- Jul 2023
- Locations
- 1 site, United States
- Primary endpoint
- Change in Oral Disposition Index (oDI)